TWYNSTA
LOE ApproachingNDAORALTABLET
Approved
Oct 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TWYNSTA is a fixed-dose combination oral tablet approved by the FDA in 2009 as a small-molecule therapeutic. The exact indications and mechanism of action are not publicly specified in available data, but it is marketed by Boehringer Ingelheim as an NDA product. The drug is currently approaching loss of exclusivity, indicating maturation in its lifecycle.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), signaling need for defensive positioning and potential restructuring of commercial teams as generic/biosimilar entry looms.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension
Started Mar 2011
2,089 enrolled
Hypertension
A Regulatory Requirement Post-Marketing Surveillance Study to Monitor the Safety and Efficacy of Twynsta (Telmisartan + Amlodipine SPC, q.d.) in Korean Hypertensive Patients Requiring Combination Therapy
Started Dec 2010
674 enrolled
Hypertension
Career Relevance
Working on TWYNSTA offers exposure to mature brand management and defensive commercial strategy in a LOE-approaching environment. Roles on this product provide experience in lifecycle optimization, pricing strategy, and generic/competitive transition planning—valuable skills for career progression into senior leadership or portfolio management positions.
Worked on TWYNSTA at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.